泊马度胺、硼替佐米和低剂量地塞米松治疗来那度胺难治且暴露于蛋白酶体抑制剂的骨髓瘤
这项1期剂量递增研究评估泊马度胺、硼替佐米(皮下或静脉)和低剂量地塞米松方案,用于来那度胺难治且暴露于蛋白酶体抑制剂的复发或复发难治多发性骨髓瘤患者。34例患者入组,未出现剂量限制性毒性,最大耐受剂量定义为计划最高剂量:泊马度胺4 mg、硼替佐米1.3 mg/m2和低剂量地塞米松。总缓解率为65%,中位缓解持续时间7.4个月,方案耐受良好且有效。
要点
- 在来那度胺难治且硼替佐米暴露的复发或复发难治多发性骨髓瘤患者中,总缓解率为65%。
- 中位缓解持续时间为7.4个月。
- 最常见的3/4级治疗中出现的不良事件为中性粒细胞减少(44%)和血小板减少(26%),静脉硼替佐米较皮下更常见。
核心结论
- 泊马度胺、硼替佐米和低剂量地塞米松方案在来那度胺难治且硼替佐米暴露的复发或复发难治多发性骨髓瘤患者中耐受良好且有效。
研究设计与样本
- 这项1期剂量递增研究评估泊马度胺、硼替佐米(皮下或静脉)和低剂量地塞米松方案,用于来那度胺难治且暴露于蛋白酶体抑制剂的复发或复发难治多发性骨髓瘤患者;共34例患者入组,其中剂量递增阶段12例、最大耐受剂量静脉硼替佐米队列10例、最大耐受剂量皮下硼替佐米队列12例。
主要发现
- 未出现剂量限制性毒性,最大耐受剂量定义为计划最高剂量:泊马度胺4 mg、硼替佐米1.3 mg/m2和低剂量地塞米松。
- 所有患者在数据截止时(2015年4月2日)均已停止治疗。
- 最常见的3/4级治疗中出现的不良事件为中性粒细胞减少(44%)和血小板减少(26%),静脉硼替佐米较皮下硼替佐米更常见。
- 未报告3/4级周围神经病变或深静脉血栓形成。
- 总缓解率为65%,中位缓解持续时间为7.4个月。
关键数值与推荐
- 最大耐受剂量定义为计划最高剂量:泊马度胺4 mg、硼替佐米1.3 mg/m2和低剂量地塞米松。
- 总缓解率为65%,中位缓解持续时间为7.4个月。
- 最常见的3/4级治疗中出现的不良事件为中性粒细胞减少(44%)和血小板减少(26%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This phase 1 dose-escalation study evaluated pomalidomide, bortezomib (subcutaneous (SC) or intravenous (IV)) and low-dose dexamethasone (LoDEX) in lenalidomide-refractory and proteasome inhibitor-exposed relapsed or relapsed and refractory multiple myeloma (RRMM). In 21-day cycles, patients received pomalidomide (1-4 mg days 1-14), bortezomib (1-1.3 mg/m2 days 1, 4, 8 and 11 for cycles 1-8; days 1 and 8 for cycle ⩾9) and LoDEX. Primary endpoint was to determine the maximum tolerated dose (MTD). Thirty-four patients enrolled: 12 during escalation, 10 in the MTD IV bortezomib cohort and 12 in the MTD SC bortezomib cohort. Patients received a median of 2 prior lines of therapy; 97% bortezomib exposed. With no dose-limiting toxicities, MTD was defined as the maximum planned dose: pomalidomide 4 mg, bortezomib 1.3 mg/m2 and LoDEX. All patients discontinued treatment by data cutoff (2 April 2015). The most common grade 3/4 treatment-emergent adverse events were neutropenia (44%) and thrombocytopenia (26%), which occurred more frequently with IV than SC bortezomib. No grade 3/4 peripheral neuropathy or deep vein thrombosis was reported. Overall response rate was 65%. Median duration of response was 7.4 months. Pomalidomide, bortezomib and LoDEX was well tolerated and effective in lenalidomide-refractory and bortezomib-exposed patients with RRMM.
引用
- Richardson PG, Hofmeister CC, Raje NS, et al. Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. Leukemia. 2017. PMID: 28642620. doi:10.1038/leu.2017.173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。